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Trials in castration-resistant prostate cancer (CRPC) treatment have shown improved 20 
outcomes including survival. However, trial populations are selected and therefore results 21 
may not be representative for the real world population.  22 
 23 
Objective 24 
To assess the differences in a real world CRPC population between patients treated in a 25 
clinical trial versus standard care during the course of CRPC. 26 
 27 
Design, setting and participants 28 
A population based sample is registered in the observational, retrospective CAPRI registry. 29 
CRPC patients from 20 hospitals in the Netherlands have been included from 2010 to 2013.  30 
 31 
Outcome measurements and statistical analysis 32 
Baseline characteristics, systemic treatment and overall survival (OS) were the main 33 
outcomes. Descriptive statistics, multivariate Cox regression and multiple imputation by 34 
Monte Carlo Markov Chain method were used. 35 
 36 
Results and limitation 37 
Of the total 1,524 patients, 203 patients had been enrolled in trials at any time during a 38 
median follow up period of 23 months. Patients in the trial subgroup were significantly 39 
younger and had less comorbidity. Docetaxel treatment was more frequent in trial patients 40 
(85% vs 40%). Despite an observed unadjusted median OS difference of 35 versus 24 months 41 
between the trial and standard care subgroup, this difference was not retained after adjustment 42 
for baseline differences and treatment effect. 43 
 44 
Conclusions 45 
At CRPC diagnosis, baseline characteristics of patients who are enrolled in trials notably 46 
differ from patients who receive standard treatment options only. The survival difference 47 
between the trial and standard care subgroup could be explained by baseline differences and 48 
treatment effect. These results indicate that trial results cannot easily be translated to real 49 
world practice. 50 
 51 
Patient summary 52 
We observed that patients treated in clinical trials differ from patients who are not. We 53 
conclude that this may lead to differential treatment and survival. This warrants caution when 54 
comparing real world outcomes to trial results.55 
Introduction 56 
 57 
Prostate cancer is a common cause of cancer in men[1]. The incidence and mortality in the 58 
Netherlands in 2010 were 104 and 25 per 100,000 (European Standardized Rate), respectively 59 
[2]. Relative survival for patients with prostate cancer in the Netherlands and Europe is 60 
comparable [3]. 61 
 62 
The first palliative treatment in metastatic prostate cancer is androgen deprivation therapy 63 
(ADT) by either medical or surgical castration. The addition of chemotherapy in hormone 64 
sensitive metastatic prostate cancer was not applicable in the study period. Once progression 65 
on ADT occurs the condition is known as castration-resistant prostate cancer (CRPC). Key 66 
items in the definition of CRPC are a castration level of testosterone and a rising PSA 67 
(biochemical progression) and/or radiologic progression [4-7]. 68 
 69 
Treatment recommendations depend mainly on the presence of metastases and the presence of 70 
symptoms, and include (year of introduction in the Netherlands in brackets): secondary 71 
hormonal manipulations (including abiraterone (post-docetaxel 2012, chemotherapy naïve 72 
2013) and enzalutamide (post-docetaxel 2013, chemotherapy naïve 2014)), chemotherapy 73 
(including docetaxel (2005) and cabazitaxel (2011)), bone directed therapy (including radium-74 
223 (2014)), immune therapy (sipuleucel-T, not available in the Netherlands during the study 75 
period) and treatment in clinical trials [4-7]. 76 
 77 
Trial outcomes form the basis of guidelines and treatment decisions in daily practice. 78 
However, trial populations are selected and therefore results may not be representative for the 79 
real world population [8]. Moreover, new treatment options in CRPC have changed treatment 80 
practice and thus influence baseline and post treatment characteristics. Real world data on 81 
CRPC patient characteristics, treatment and outcomes are scarce, and reports are often 82 
outdated [9]. Therefore we have initiated the CAPRI registry to investigate the clinical 83 
outcomes, treatment patterns and economic outcomes of CRPC treatment in daily practice. 84 
 85 
In this paper we report the first results of the CAPRI registry. The aim of this analysis is to 86 
assess differences in baseline characteristics at CRPC diagnosis, systemic treatment and 87 
survival in patients treated in trials versus standard care during the course of CRPC. 88 
 89 
90 
Methods  91 
 92 
Study design and setting 93 
CAPRI (CAstration-resistant Prostate cancer RegIstry) is an investigator-initiated, 94 
observational multi-center cohort study in 20 hospitals in the Netherlands. Before the start of 95 
the study, 20 hospitals were selected on the basis of geographical spread, as well as by type of 96 
hospital (both general and academic hospitals) and accepted the invitation. Data collection 97 
started after approval by the local medical ethics committee and hospital board. Patients were 98 
retrospective included from January 1st, 2010 and data has been regularly updated for all 99 
patients from 2013 to 2015. The study population is an estimated 20% sample of all CRPC 100 
patients in the Netherlands in the study period. The study is registered in the Dutch Trial 101 
Registry as NTR3591. 102 
 103 
Objective 104 
To assess the differences in a real world CRPC population between patients treated in a 105 
clinical trial (“trial”) versus standard care during the course of CRPC. 106 
 107 
Participants 108 
Patients were screened for inclusion in both the urology and medical oncology departments of 109 
each hospital, and were identified by the diagnosis code prostate cancer from the hospital 110 
information systems based on encoded “Diagnosis Treatment Combinations”, a nationwide 111 
coding and reimbursement system providing information about the type of care, diagnosis and 112 
all treatment modalities. Eligible patients had to be diagnosed with prostate cancer (defined as 113 
histologic confirmation of prostate cancer or as concluded by the treating doctor based on 114 
elevated PSA and metastatic pattern), and had disease progression despite ADT. Disease 115 
progression was defined as in the EAU CRPC definition [6], or as progression according to 116 
the treating doctor. Anti-androgen therapy following progression on ADT was considered first 117 
line systemic therapy for CRPC. In addition, patients had to be diagnosed with CRPC in years 118 
2010, 2011 or 2012 and have more than two outpatient clinic visits. Eligible patients treated in 119 
more than 1 hospital were included only once. 120 
 121 
If a patient was enrolled in a phase 1, 2 or 3 trial during the follow up period, the patient was 122 
assigned to the “trial” subgroup, otherwise the patient was assigned to the “standard care” 123 
subgroup. 124 
 125 
Follow up and data collection 126 
Predefined and readily available data from medical records were retrospectively collected by 127 
trained data managers. Database cut-off was set on March 1st, 2015. See Appendix 1 for full 128 
overview of data variables. 129 
 130 
Study size 131 
Here we report the first analysis after registration of the first 1,524 consecutive patients. 132 
 133 
Statistics 134 
Descriptive statistics were used. Differences in subgroups were tested for significance by 135 
either Chi-square test (categorical variables) or Mann-Whitney U (continuous variables). 136 
Survival analyses were done by Kaplan-Meier methods and Cox regression analyses. 137 
Differences were considered of statistical significance at a p-value of 0.05 or less. 138 
For imputation of missing baseline characteristics, multiple imputation by Monte Carlo 139 
Markov Chain method was used as described before [10]. For statistical analyses, IBM SPSS 140 
Statistics version 22 was used. 141 
Results  142 
 143 
At the time of this analysis (March 2015), 29,565 prostate cancer patients were identified in 144 
20 hospitals (11 large teaching hospitals, 5 general hospitals and 4 academic hospitals). A 145 
flow diagram of the screened population, exclusion and inclusion of patients is shown in 146 
Figure 1.  147 
 148 
1,524 CRPC patients were included, diagnosed with CRPC in 2010 (30%), 2011 (37%) or 149 
2012 (33%). Of all patients, 203 (13%) had been treated in at least one trial (range 1-4; 48 150 
patients participated in more than 1 trial) during the course of disease (trial subgroup). The 151 
remaining 87% patients had not been treated in a trial (standard care subgroup). The most 152 
common trials are shown in supplementary Table S4. Life prolonging drugs have been given 153 
to patients in the trial subgroup in both trials and as standard care: docetaxel 46/173 (27%) in 154 
trials, cabazitaxel 69/94 (73%) in trials, abiraterone 3/114 (3%) in trials, enzalutamide 0/46 155 
(0%) in trials and radium-223 4/7 (57%) in trials. Life-prolonging drugs have been given as 156 
study drug in randomized placebo-controlled trials in a minority of cases (abiraterone/placebo 157 
n=5, enzalutamide/placebo n=18). 158 
 159 
The median follow up period from CRPC diagnosis was 23 months (Inter quartile range 160 
(IQR) 11 to 34 months). At the time of the database cutoff, 983 deaths (65%) had occurred, 161 
180 patients (12%) were lost to follow up and 361 patients (24%) were still in follow up with 162 
a median follow up period of 39 months (range 26 – 62 months). 163 
 164 
Baseline characteristics 165 
Baseline characteristics of the patients at CRPC diagnosis, and differences between the two 166 
subgroups, are shown in Table 1. Distribution of CRPC criteria are provided in supplementary 167 
Table S5. The population includes 6% of patients without a histologic diagnosis of prostate 168 
cancer and 4% with unknown histologic status, thus included on the basis of PSA and clinical 169 
characteristics alone. Testosterone was not measured in 51% at baseline, however in 10% of 170 
patients testosterone was measured later in the course of CRPC. Patients in the trial subgroup 171 
were significantly younger (67 vs 76 years, p<0.001) and had less comorbidity (No 172 
comorbidity 76% vs 54%, p<0.001). At CRPC diagnosis, patients in the trial subgroup had 173 
higher hemoglobin (8.4 vs. 8.0 mmol/L, p<0.001), lower LDH (215 vs 228 U/L, p=0.033), 174 
and better clinical performance score (ECOG ≥2 2% vs 7%, p=0.015). 175 
 176 
Treatment  177 
All systemic treatments until end of follow up are summarized in Table 2.  178 
 179 
During the follow up period, 46% of all patients had been treated with docetaxel. In the trial 180 
subgroup, 85% of patients were treated with docetaxel as compared to 40% of patients in the 181 
standard care subgroup (p<0.001). In the trial subgroup, cabazitaxel (46% vs 7%, p<0.001), 182 
abiraterone post-docetaxel (50% vs 22%, p<0.001), enzalutamide post-docetaxel (20% vs 183 
15%, p<0.001), enzalutamide chemo-naïve (5% vs 1%, p<0.001) and radium-223 post-184 
docetaxel (3% vs 1%, p=0.003) were initiated more often, whereas prescription of abiraterone 185 
(6% vs 8%, p=0.419)and radium-223 (0% vs <1%, p=0.377) in chemotherapy-naïve patients 186 
was more equally spread. 187 
 188 
Survival 189 
Median overall survival (OS) of all patients was 26 months (IQR 12 – 48 months). Median 190 
OS was 35 months (IQR 21 –60 months) for the trial subgroup, as compared to 24 months 191 
(IQR 12 – 48 months) for the standard care subgroup (p<0.001), and is shown in Figure 2. 192 
Univariate analysis of baseline variables, trial enrollment and treatment strategy were done: 193 
the variables were dichotomized and patients with missing values were separately analyzed 194 
(see supplementary Table S6). After multiple imputation of missing values, we performed 195 
multivariate analysis of the pooled imputed data. After correction for baseline differences, 196 
independent significant prognostic factors for survival were Gleason score, period on ADT, 197 
hemoglobin, alkaline phosphatase (ALP), PSA and ECOG performance status (see Table 3). 198 
Treatment with abiraterone, enzalutamide and radium-223 in chemotherapy-naïve patients, as 199 
well as treatment with cabazitaxel, abiraterone, enzalutamide and radium-223 post-docetaxel 200 
was associated with longer survival (Hazard ratio (HR) 0.53; p<0.0001 and HR 0.46; 201 
p<0.0001, respectively). However, trial enrollment was no longer significant for OS (HR 202 





To our knowledge, this is the first registry of this size in which outcomes are registered 208 
independent of the treating doctors. The design of the registry allowed the inclusion of 209 
patients without histologic confirmation of prostate cancer or not meeting the CRPC 210 
definition by the EAU but regarded as CRPC by the treating doctor. Therefore, the outcomes 211 
in this study truly reflect daily practice.  212 
 213 
The population includes 6% of patients without a histologic diagnosis of prostate cancer and 214 
41% without measurement of testosterone during the course of disease. It is unlikely that 215 
patients are enrolled in trials without histological diagnosis or without an objective CRPC 216 
status, however the baseline period in our study (90 days before to 90 days after CRPC 217 
diagnosis) differs from the date of trial enrollment. This explains missing or unknown data on 218 
CRPC status in the trial subgroup.  219 
 220 
We observed a median OS in the total population of 26 months, and a significant longer OS in 221 
the trial subgroup compared to standard care (35 vs 24 months, p<0.001). This difference may 222 
at least partly be explained by confounding factors, including baseline differences or 223 
differences in treatment. After correction for baseline prognostic factors and treatment effect, 224 
trial participation was not associated with a significantly lower risk of death (HR 0.95, 225 
p=0.658). 226 
 227 
Trial patients differed mainly from standard care patients with regards to age (67 vs 76 years), 228 
comorbidity (no comorbidity 76% vs 54%) and treatment strategy (docetaxel treatment 85% 229 
vs 40%).  230 
 231 
Baseline characteristics of recent clinical trials in docetaxel-naïve populations are relatively 232 
similar to this study, particularly to the trial subgroup [11-13]. The median OS in the trial 233 
subgroup of 35 months compares slightly favorably to the median OS of the trial comparator 234 
arms in chemotherapy-naïve CRPC trials of 21.7 to 30.2 months [11-13]. We observed 235 
subsequent docetaxel therapy in the trial subgroup in 85% of patients, whereas subsequent 236 
therapy with docetaxel in the comparator arms of the trials ranged from 50 to 57% [11-13]. In 237 
a single-center analysis of trial participants only, chemotherapy-naïve CRPC patients (median 238 
age 67 years) had a median OS of 30.6 months and subsequent docetaxel treatment was given 239 
in 64% [14]. In conclusion, the baseline characteristics, systemic treatment and outcomes of 240 
our trial subgroup are representative for known trial populations. 241 
 242 
Missing values are a limitation of our study. This is inherent to the retrospective method of 243 
the study. For this analysis, we have analyzed baseline differences at the moment of CRPC 244 
diagnosis, not at the start of each subsequent treatment. In the baseline period, evaluation of 245 
disease stage (CT-scan and bone scintigraphy) and laboratory parameters (hemoglobin, ALP, 246 
LDH), as well as performance status registration, were frequently incomplete. LDH and 247 
visceral disease status were missing in >50% of cases, but were included because of known 248 
prognostic relevance. Missing values were less frequent at the start of subsequent treatment, 249 
especially in life-prolonging drugs (data not shown), reflecting daily practice and the absence 250 
of direct need of documentation of these parameters at progression on ADT. Gleason scores 251 
may be missing if no histologic biopsy was taken, or if the biopsy dates from the period prior 252 
to the introduction of the Gleason scoring system in 2004 [15]. However, we adapted tumor 253 
grades to Gleason scores if possible (see Appendix 1). When excluding all patients with 254 
missing values in prognostic factors, only 113 patients were available for multivariate 255 
analysis, which consequently lacked statistical power. Imputation of missing data provides a 256 
valid and reproducible solution for this problem, allowing multivariate analysis on the 257 
complete study population [10].  258 
 259 
Known predictors of survival in metastatic CRPC include disease site (visceral disease), 260 
Gleason score, performance status, ALP, hemoglobin, PSA and LDH [16]. After imputation 261 
of missing values, we confirmed these predictors of survival in our population (see 262 
supplementary Table S7). Moreover, after correction for baseline differences, independent 263 
significant prognostic factors for survival did also include period on ADT.  264 
 265 
The treatment effect is difficult to assess in this analysis. Treatments were given sequentially 266 
with differential sequences in a non-protocolled manner. Therefore we analyzed the 267 
prescription of life-prolonging drugs (abiraterone, enzalutamide, radium-223, docetaxel and 268 
cabazitaxel) as a proxy for treatment effect. We observed that patients in the trial subgroup 269 
were treated with more treatment lines and more life-prolonging drugs. Treatment with life-270 
prolonging drugs was associated with increased survival in multivariate analysis. 271 
 272 
Trial patients were enrolled in more than 15 different trials. A total of 264 trial treatments 273 
were registered, with a substantial number of treatments in a trial with survival benefit but 274 
placebo-controlled (n=28), a trial with no difference in outcome between the study arms 275 
(n=96) or a trial that has no results yet (n=93). Although we did not aim to answer the 276 
question if trial participation is an independent prognostic factor for survival, we hypothesize 277 
that placebo treatment or treatment in trials without proven survival benefit over standard 278 
treatment may have diluted a positive effect of trial treatment on survival, if present.   279 
 280 
Based on a systematic review in 2001, it was concluded that there is weak evidence to suggest 281 
that clinical trials have a positive effect on the outcome of participants, possibly through 282 
enhancing quality of care, stringent patient selection criteria, and adapting aggressive 283 
measures for treating patients in trials [17]. Two recent reports on patients treated with 284 
docetaxel for metastatic CRPC either in a trial or outside a trial resulted in improved OS for 285 
trial participants [18;19]. In our study participation in trials does not yield survival benefit 286 
after adjusting for baseline characteristics and treatments received. We hypothesize that this 287 
may reflect the high availability of novel treatment options and mandatory health care 288 
insurance in the Netherlands. A limitation may therefore be the lack of external validity to 289 
populations outside the Netherlands, especially those populations with different access to 290 
healthcare.  291 
 292 
In conclusion, we have shown that baseline characteristics of patients enrolled in a trial differ 293 
from patients who are not, as well as the percentage of patients treated with docetaxel. The 294 
difference in OS between trial patients and standard care patients did not retain statistical 295 
significance after correction for baseline differences and treatment effect. These results may 296 
indicate that trial results cannot easily be translated to real world practice. Further studies are 297 
needed to assess clinical outcomes, patient reported outcomes and cost-effectiveness of 298 
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